

# Thomas J Moore

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7657471/publications.pdf>

Version: 2024-02-01

39  
papers

4,573  
citations

279798

23  
h-index

315739

38  
g-index

40  
all docs

40  
docs citations

40  
times ranked

5854  
citing authors

#	ARTICLE	IF	CITATIONS
1	Author Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease. <i>Neurology</i> , 2022, 98, 49-50.	1.1	0
2	Safety and effectiveness of <scp>NMDA</scp> receptor antagonists for depression: A multidisciplinary review. <i>Pharmacotherapy</i> , 2022, 42, 567-579.	2.6	8
3	Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products. <i>JAMA Internal Medicine</i> , 2021, 181, 52.	5.1	25
4	Association of Pharmaceutical Industry Payments to Physicians With Prescription and Medicare Expenditures for Pimavanserin. <i>Psychiatric Services</i> , 2021, 72, 77-80.	2.0	2
5	Changes in medical use of central nervous system stimulants among US adults, 2013 and 2018: a cross-sectional study. <i>BMJ Open</i> , 2021, 11, e048528.	1.9	5
6	Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease. <i>Neurology</i> , 2021, 97, e1266-e1275.	1.1	29
7	Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication. <i>JAMA Oncology</i> , 2021, 7, 1720-1721.	7.1	4
8	Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018. <i>Annals of Internal Medicine</i> , 2020, 173, 956-963.	3.9	2
9	Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015â€“2017: a cross-sectional study. <i>BMJ Open</i> , 2020, 10, e038863.	1.9	38
10	Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis. <i>BMJ Open</i> , 2020, 10, e039978.	1.9	42
11	US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS). <i>Pharmaceutical Medicine</i> , 2020, 34, 135-140.	1.9	9
12	Estimated costs of pivotal trials for U.S. Food and Drug Administrationâ€“approved cancer drugs, 2015â€“2017. <i>Clinical Trials</i> , 2020, 17, 119-125.	1.6	12
13	Globalization of clinical trials: Variation in estimated regional costs of pivotal trials, 2015â€“2016. <i>Clinical Trials</i> , 2019, 16, 329-333.	1.6	12
14	Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016. <i>JAMA Internal Medicine</i> , 2018, 178, 1451.	5.1	219
15	Assessment of Patterns of Potentially Unsafe Use of Zolpidem. <i>JAMA Internal Medicine</i> , 2018, 178, 1275.	5.1	18
16	Adult Utilization of Psychiatric Drugs and Differences by Sex, Age, and Race. <i>JAMA Internal Medicine</i> , 2017, 177, 274.	5.1	163
17	The Fate of FDA Postapproval Studies. <i>New England Journal of Medicine</i> , 2017, 377, 1114-1117.	27.0	64
18	The Harms of Antipsychotic Drugs: Evidence from Key Studies. <i>Drug Safety</i> , 2017, 40, 3-14.	3.2	7

#	ARTICLE	IF	CITATIONS
19	Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 713-718.	1.9	33
20	Electronic Health Data for Postmarket Surveillance: A Vision Not Realized. <i>Drug Safety</i> , 2015, 38, 601-610.	3.2	36
21	Antidepressants increase, rather than decrease, risk of suicidal behaviours in younger patients. <i>BMJ, The</i> , 2014, 349, g5626-g5626.	6.0	2
22	Reports of Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs. <i>JAMA Internal Medicine</i> , 2014, 174, 1930.	5.1	246
23	Dabigatran, bleeding, and the regulators. <i>BMJ, The</i> , 2014, 349, g4517-g4517.	6.0	70
24	Underreporting of Hemorrhagic and Thrombotic Complications of Pharmaceuticals to the U.S. Food and Drug Administration: Empirical Findings for Warfarin, Clopidogrel, Ticlopidine, and Thalidomide from the Southern Network on Adverse Reactions (SONAR). <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 905-907.	2.7	28
25	New Drug: Caution Indicated. <i>Archives of Internal Medicine</i> , 2012, 172, 1681.	3.8	1
26	The FDA and New Safety Warnings. <i>Archives of Internal Medicine</i> , 2012, 172, 78.	3.8	43
27	Suicidal Behavior and Depression in Smoking Cessation Treatments. <i>PLoS ONE</i> , 2011, 6, e27016.	2.5	128
28	Prescription Drugs Associated with Reports of Violence Towards Others. <i>PLoS ONE</i> , 2010, 5, e15337.	2.5	75
29	Thoughts and Acts of Aggression/Violence Toward Others Reported in Association with Varenicline. <i>Annals of Pharmacotherapy</i> , 2010, 44, 1389-1394.	1.9	29
30	Iatrogenic Effects of COX-2 Inhibitors in the US Population. <i>Drug Safety</i> , 2009, 32, 335-343.	3.2	24
31	Risk of psychiatric side effects with varenicline. <i>BMJ: British Medical Journal</i> , 2009, 339, b4964-b4964.	2.3	23
32	Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration. <i>PLoS Medicine</i> , 2008, 5, e45.	8.4	1,935
33	Serious Adverse Drug Events Reported to the Food and Drug Administration, 1998-2005. <i>Archives of Internal Medicine</i> , 2007, 167, 1752.	3.8	376
34	Reported medication errors associated with methotrexate. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 1380-1384.	1.0	55
35	Reported Adverse Event Cases of Methemoglobinemia Associated With Benzocaine Products. <i>Archives of Internal Medicine</i> , 2004, 164, 1192.	3.8	97
36	Reported Adverse Drug Events in Infants and Children Under 2 Years of Age. <i>Pediatrics</i> , 2002, 110, e53-e53.	2.1	111

#	ARTICLE	IF	CITATIONS
37	Effects of Diet and Sodium Intake on Blood Pressure: Subgroup Analysis of the DASH-Sodium Trial. <i>Annals of Internal Medicine</i> , 2001, 135, 1019.	3.9	475
38	Effect of Dietary Patterns on Ambulatory Blood Pressure. <i>Hypertension</i> , 1999, 34, 472-477.	2.7	124
39	Time for Action on Drug Safety—Reply. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 320.	7.4	1